NewAmsterdam Pharma Co NV

For the period ended Mar 31, 2024. Filed May 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

NAMS$19.00+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	March 31,2024	December 31,2023
(In thousands of USD)
Assets
Current assets:
Cash	481,147	340,450
Prepayments and other receivables	6,675	6,341
Total current assets	487,822	346,791
Property, plant and equipment, net	101	46
Operating right of use asset	38	55
Intangible assets	486	170
Long term prepaid expenses	16	35
Total assets	488,463	347,097
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable	8,536	16,923
Accrued expenses and other current liabilities	9,970	11,398
Deferred revenue, current	8,116	8,942
Lease liability, current	43	60
Derivative warrant liabilities	33,061	12,574
Total current liabilities	59,726	49,897
Deferred revenue, net of current portion	444	1,019
Derivative earnout liability	16,490	7,788
Total liabilities	76,660	58,704
Commitments and contingencies (Note 10)
Shareholders' Equity (deficit):
Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 89,720,836 and 82,469,768 shares issued and outstanding as at March 31, 2024 and December 31, 2023, respectively	11,113	10,173
Additional paid-in capital	807,008	590,771
Accumulated loss	(410,740)	(316,973)
Accumulated other comprehensive income (loss)	4,422	4,422
Total shareholders' equity	411,803	288,393
Total liabilities and shareholders' equity (deficit)	488,463	347,097

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.